A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Titre officiel

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Sommaire:

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Description de l'essai

Primary Outcome:

  • Median progression free survival (mPFS)
Secondary Outcome:
  • Trough observed serum concentration (Ctrough)
  • Objective response rate (ORR)
  • Median duration of response (MDOR)
  • Overall survival rate (OSR)
  • Incidence of Adverse Events (AE)
  • Incidence of Serious Adverse Events (SAE)
  • Incidence of death
  • Incidence of laboratory abnormalities
  • Incidence of Adverse Events (AE) leading to discontinuation

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer